More Post from the Author
- Keycafe Expands Executive Leadership with Appointments of Rudi Airisto and Robert Johnston as Company Enters Next Phase of Global Growth
- /C O R R E C T I O N -- Tessitura/
- CoolIT Systems Demonstrates 15kW Coldplate, Extending Single-Phase DLC Roadmap Far Beyond 2030
- EQT sets target fund size for EQT Infrastructure VII at EUR 21 billion
- Web3 Has No Safe AI. DMind AI Just Quantified the Gap -- and KDD 2026 Made It Official.
Indivior Statement RE: Delayed FDA Approval of SUBLOCADE Label Changes
Published on Wed 12 Feb 2025 8:07:04 UTC
RICHMOND, Va., Feb. 12, 2025 /PRNewswire/ --Indivior PLC (Nasdaq/LSE: INDV)provides the following update regarding its PDUFA action date for label changes (rapid initiation protocol and alternative injection sites) for SUBLOCADE (buprenorphine extended-release) Injection, which was scheduled for February 7, 2025:
Yesterday, February 11th, the FDA informed Indivior that, following acceptance of the proposed label for SUBLOCADE, there were no outstanding items to address, but that final review of the SUBLOCADE label changes has been delayed.
Indivior will provide further updates on the status of the approval of the proposed SUBLOCADE label changes as appropriate.
SOURCE Indivior PLC
More Post from the Author
- Keycafe Expands Executive Leadership with Appointments of Rudi Airisto and Robert Johnston as Company Enters Next Phase of Global Growth
- /C O R R E C T I O N -- Tessitura/
- CoolIT Systems Demonstrates 15kW Coldplate, Extending Single-Phase DLC Roadmap Far Beyond 2030
- EQT sets target fund size for EQT Infrastructure VII at EUR 21 billion
- Web3 Has No Safe AI. DMind AI Just Quantified the Gap -- and KDD 2026 Made It Official.